R&D channel feed – Endpoints News

R&D channel feed

UK biotech unveils early data for antibiotic in chronic back pain

2 months ago

PepGen delays study for Duchenne drug as it awaits safety data from another trial

2 months ago

Swiss biotech ends Phase 2 study in Alzheimer's shortly after Lilly and Biogen did the same

2 months ago

NIH-backed research tries to use stem cells to restore the eye’s outer layer

2 months ago

GSK, Amgen and AstraZeneca tout Phase 3 data in inflammatory nasal condition

2 months ago

Pliant calls it quits on Phase 2b idiopathic pulmonary fibrosis study

2 months ago

Biohaven’s ion channel drug fails pivotal bipolar mania study

2 months ago

Protagonist, Takeda's profit sharing deal under spotlight after Phase 3 blood disorder trial win

2 months ago

Novartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfront

2 months ago

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

2 months ago

Lexicon plots Phase 3 trial for diabetic pain drug despite mid-stage flop

2 months ago

Praxis says its essential tremor drug failed a Phase 3 readout, but plans to complete study

2 months ago

Verve is latest gene editing company to suffer setback, as Vertex walks away from pact

2 months ago

Kallyope quietly reports Phase 2 obesity data, begins mid-stage migraine trial

2 months ago

Startup working on oral antibodies shares early ulcerative colitis data

2 months ago

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

2 months ago

Regeneron, two Chinese biotechs tout promise of their hearing loss gene therapies

2 months ago

Candel's viral therapy shows promising survival in small pancreatic cancer study

2 months ago

Chicago biotech Emalex says it cleared a Phase 3 for Tourette syndrome, will seek FDA approval

2 months ago

Alnylam eyes bigger diseases in more tissue types at ‘inflection point’ for siRNA

2 months ago

FDA lifts hold on Entrada's Duchenne drug after two years

3 months ago

Amgen plans further $200M investment in new tech facility in India

3 months ago

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

3 months ago

FDA approves first drug to treat ultra-rare lipid storage disease

3 months ago

First page Previous page 6 7 8910 11 12 Next page Last page